FDA
-
-
-
-
-
-
-
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
-
-
-
-
-
-
-
Prothena Corp (PRTA) PT Lowered to $31 at BofA Securities
-
-
-
-
-
-
-
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
-
-
-
-
-
-
-
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
-
-
-
-
-
-
-
Prothena Reports Second Quarter 2022 Financial Results and Business Highlights
-
-
-
-
-
-
-
Prothena Corp. (PRTA) Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/12: (STFC) (CLDX) (SPI) Higher; (TBLT) (DIDI) (RKT) Lower (more...)
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

